4Dandona p, Aljada A, Chaudhuri A, et al Metabolic Syndrome;A comprehensive perspective Based on Interactions, Between Obesity, Diabetes, and Inflammation. Circ ulation,2005 ; 111 : 1448 - 1454.
10Cushman WC, Ford CE, Cutler JA, et al. Success and Predictors of blood pressure control in diverse North American settings:The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin. Hypertens ( Greenwich ) , 2002 ;4:393 - 404.
4[2]Py(o)rala K,Savolainen E,Kaukola J,et al.Plasma insulin as coronary heart disease risk factor:relationship to other risk factors and predictive value during 9 1/2-year follow-up of the Helsinki Policemen Study population[J].Acta Med Scand,1985,701:S38-52.
5[3]Verdecehia P,Rreboldi G,Angeli F,et al.Adverse prognostic significance of new diabetes in treated hypertensive subjects[J].Hypertension,2004,43:963-969.
6[4]Bartnik M,Ryden L,Ferrari R,et al.The prevalence of abnorreal glucose regulation in patients with coronary artery disease across Europe.The Euro Heart Survey on diabetes and the heart[J].Eur Heart J,2004,25:1880-1890.
7[5]Chiasson JL,Josse RG,Gomis R,et al.STOP-NIDDM trial research group:acarbose for prevention of type 2 diabetes mellitus:the STOP-NIDDM randomised trial[J].Lancet,2002,359:2072-2077.
8[6]Hanefeld M,Fischer S,Schmechel H,et al.Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance:the STop-NIDDM trial[J].J Am Med Assoc,2003,290:486-494.
9Swislocki A. Insulin resistance and hypertension[J]. Am J Med Sci, 1990,300(2) : 104- 115.
10Andersen UB,Dige-Petersen H, Ibsen H, et al. Insulin resistance, exercise capacity and body composition in subjects with two hypertensive parents [ J ]. J Hypertens, 1999, 17 ( 9 ) : 1 273-1 280.
